Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM54 in advanced solid tumors
NCT05841563Phase 1Recruiting
- Sponsor
- PharmaMar
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of PM54 in urothelial carcinoma (UC), clear cell renal cell carcinoma (ccRCC), prostate adenocarcinoma and 18 more, sponsored by PharmaMar. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 21 days and 10 more. Started Apr 2023; status: recruiting.
02
Drugs
PM54
03
Conditions
urothelial carcinoma (UC)clear cell renal cell carcinoma (ccRCC)prostate adenocarcinomacutaneous melanoma (CM)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05841563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841563.